This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically application US20260083758A1, filed by Harmony Biosciences Management, Inc. The application describes methods for treating SYNGAP1 encephalopathy by administering cannabidiol (CBD) transdermally to a subject. The filing date was November 28, 2025, and the publication date is March 26, 2026.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in the treatment of SYNGAP1 encephalopathy and may be of interest to pharmaceutical companies, medical device manufacturers, and researchers in the neurology and rare disease space. Compliance officers should note this as a potential future product or therapeutic area.